1 Introduction 10

• 1.1 Industry Definition and Research Scope 10
  • 1.1.1 Industry Definition 10
  • 1.1.2 Research Scope 11
• 1.2 Research Methodology 14
  • 1.2.1 Overview of Market Research Methodology 14
  • 1.2.2 Market Assumption 15
  • 1.2.3 Secondary Data 15
  • 1.2.4 Primary Data 15
  • 1.2.5 Data Filtration and Model Design 17
  • 1.2.6 Market Size/Share Estimation 18
  • 1.2.7 Research Limitations 19
• 1.3 Executive Summary 20

2 Market Overview and Dynamics 23

• 2.1 Market Size and Forecast 23
  • 2.1.1 Impact of COVID-19 on the Market 28
• 2.2 Major Growth Drivers 30
• 2.3 Market Restraints and Challenges 35
• 2.4 Emerging Opportunities and Market Trends 40
• 2.5 Porter’s Fiver Forces Analysis 44

3 Segmentation of Global Market by System Component 48

• 3.1 Market Overview by System Component 48
• 3.2 Data Collection Tools 50
  • 3.2.1 Digital Platforms 52
  • 3.2.2 Mobile Apps 53
  • 3.2.3 Desktop-based Software 54
  • 3.2.4 Wearables 55
  • 3.2.5 Biosensors 56
• 3.3 Data Integration Systems 57

4 Segmentation of Global Market by Therapeutic Area 58

• 4.1 Market Overview by Therapeutic Area 58
• 4.2 Cardiovascular Diseases 60
• 4.3 Neurodegenerative Disorders 61
  • 4.3.1 Parkinson’s Disease 63
  • 4.3.2 Multiple Sclerosis 64
  • 4.3.3 Alzheimer’s Disease 65
• 4.4 Sleep and Movement Diseases 66
• 4.5 Psychiatric Disorders 67
• 4.6 Chronic Pain 68
• 4.7 Gastrointestinal Diseases 69
• 4.8 Diabetes 70
• 4.9 Respiratory Conditions 71
• 4.10 Other Diseases 72

5 Segmentation of Global Market by Application 73

• 5.1 Market Overview by Application 73
• 5.2 Wellness 75
• 5.3 Disease Diagnosis 76
• 5.4 Personalised Medication 77
• 5.5 Drug Discovery and Development 78

6 Segmentation of Global Market by Development Status 80

• 6.1 Market Overview by Development Status 80
• 6.2 Novel Digital Biomarkers 83
• 6.3 Original Digital Biomarkers 84
• 6.4 Approved Digital Biomarkers 85

7 Segmentation of Global Market by End User 86

• 7.1 Market Overview by End User 86
• 7.2 Biopharmaceutical Companies & Labs 88
• 7.3 Healthcare Providers 89
• 7.4 Insurance Payers 90

8 Segmentation of Global Market by Region 91

• 8.1 Geographic Market Overview 2019-2030 91
• 8.2 North America Market 2019-2030 by Country 95
  • 8.2.1 Overview of North America Market 95
  • 8.2.2 U.S. 99
  • 8.2.3 Canada 103
  • 8.2.4 Mexico 105
• 8.3 European Market 2019-2030 by Country 107
  • 8.3.1 Overview of European Market 107
  • 8.3.2 Germany 111
  • 8.3.3 UK 113
  • 8.3.4 France 115
  • 8.3.5 Netherlands 117
  • 8.3.6 Italy 119
  • 8.3.7 Russia 121
  • 8.3.8 Rest of European Market 123
• 8.4 Asia-Pacific Market 2019-2030 by Country 125
  • 8.4.1 Overview of Asia-Pacific Market 125
  • 8.4.2 Japan 129
  • 8.4.3 China 132
  • 8.4.4 Australia 134
  • 8.4.5 India 136
  • 8.4.6 South Korea 138
  • 8.4.7 Rest of APAC Region 140
• 8.5 South America Market 2019-2030 by Country 142
  • 8.5.1 Argentina 145
  • 8.5.2 Brazil 147
  • 8.5.3 Chile 149
  • 8.5.4 Rest of South America Market 151
• 8.6 MEA Market 2019-2030 by Country 152
  • 8.6.1 UAE 155
  • 8.6.2 Saudi Arabia 157
  • 8.6.3 Israel 159
  • 8.6.4 Other National Markets 161

9 Competitive Landscape 162

• 9.1 Overview of Key Vendors 162
• 9.2 New Product Launch, Partnership, Investment, and M&A 166
• 9.3 Company Profiles 167

Actigraph LLC 167

Akili Interactive Labs 169

AliveCor Inc 170

Altoida Inc 171

Amgen Inc 172

Bayer AG 173

Biogen Inc 174

Cambridge Cognition Plc 175

Eli Lilly and Company 176

Evidation Health, Inc. 177

F. Hoffmann-La Roche Ltd 178

Fitbit Inc 179

GlaxoSmithKline Plc 180

Happify Health 181

Human API 182

IXICO Plc 183

Koninklijke Philips N.V. 184

Medical Care Corporation 185

Medopad Ltd 186

Mindstrong Health 187

Neurotrack Technology, Inc 188

Novartis International AG 189

Pfizer Inc. 190

Quanterix Corporation 191

Sanofi S.A. 192

The Takeda Pharmaceuticals Company Limited 193

Verily Life Sciences 194

Winterlight Labs Inc. 195

10 Investing in Global Market: Risk Assessment and Management 196

• 10.1 Risk Evaluation of Global Market 196
• 10.2 Critical Success Factors (CSFs) 199

Related Reports and Products 199

Global digital biomarkers market will reach $22.54 billion by 2030, growing by 36.2% annually over 2020-2030 driven by rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare.
Highlighted with 91 tables and 99 figures, this 199-page report “Global Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Region.

Based on System Component, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Data Collection Tools
• Digital Platforms
• Mobile Apps
• Desktop-based Software
• Wearables
• Biosensors
Data Integration Systems

Based on Therapeutic Area, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cardiovascular Diseases
Neurodegenerative Disorders
• Parkinson’s Disease
• Multiple Sclerosis
• Alzheimer’s Disease
Sleep and Movement Diseases
Psychiatric Disorders
Chronic Pain
Gastrointestinal Diseases
Diabetes
Respiratory Conditions
Other Diseases

Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Wellness
• Disease Diagnosis
• Personalised Medication
• Drug Discovery and Development

Based on Development Status, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Novel Digital Biomarkers
• Original Digital Biomarkers
• Approved Digital Biomarkers

Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Biopharmaceutical Companies & Labs
• Healthcare Providers
• Insurance Payers

Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, The Netherlands, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• RoW (Saudi Arabia, UAE, Israel)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)